2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

The 2015 MASCC–ESMO guideline for the prevention of ChT- and RINV was updated based on a literature search from 1 June 2015 through 31 January 2023. Thirty-four multidisciplinary experts reviewed the literature. The most important updates were as follows:1)Recommendation to use olanzapine as part of the prophylaxis for patients receiving HEC;2)Recommendation of a 1-day DEX schedule in patients treated with AC, carboplatin or other MEC;3)Suggestion to include an NK1-RA in the antiemetic regimen for women aged ≤50 years receiving oxaliplatin;4)Suggestion to use olanzapine for breakthrough CINV;5)For the first time providing suggestions for the use of some integrative and non-pharmacological therapies;…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• AS
  American Society of Clinical Oncology
• H
  Helsinn
• ES
  European Society for Medical Oncology
• NN
  Novo Nordisk Fonden
• DS
  Daiichi Sankyo Europe